TNF Pharmaceuticals Holds Shareholder Vote on Reverse Split
Ticker: QCLS · Form: 8-K · Filed: Jun 6, 2025 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, reverse-split, shareholder-meeting
TL;DR
TNF Pharma calling shareholder vote for reverse split & charter amendment. Big changes coming.
AI Summary
On June 3, 2025, TNF Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced a special meeting of stockholders to vote on proposals including a reverse stock split and an amendment to its certificate of incorporation. Additionally, the filing includes financial statements and exhibits related to these corporate actions.
Why It Matters
This filing indicates significant corporate restructuring, potentially impacting share price and investor holdings.
Risk Assessment
Risk Level: medium — Reverse stock splits can signal financial distress or a strategy to meet exchange listing requirements, which carries inherent risk.
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Registrant
- June 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36268 (identifier) — SEC file number
FAQ
What is the primary purpose of the special meeting of stockholders?
The primary purpose is for stockholders to vote on proposals including a reverse stock split and an amendment to the company's certificate of incorporation.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 3, 2025.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the SEC file number for TNF Pharmaceuticals, Inc.?
The SEC file number is 001-36268.
What other former company names has TNF Pharmaceuticals, Inc. used?
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and Akers Biosciences, Inc.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 6, 2025 regarding TNF Pharmaceuticals, Inc. (QCLS).